Nesta página
CRL Charles River Laboratories International, Inc. Common Stock
NYSE · Life Sciences Tools & Services · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 5, 2026
$290,19
· % da faixa de 52 semanas
· acima do mínimo
· para alta
$146,20mínima 52 sem
$303,31máxima 52 sem
Capitalização de Mercado (MRQ)
$13.85B
P/E (TTM)
-60.5
EPS (TTM)
$-4.80
Receita (TTM)
$4.00B
seus distintivos
Intervalo 52 Semanas
$146–$303
Classificação do Analista
BUY
Preço-Alvo
$305
P/E
-60.5
ROE
-7.7%
Margem de Lucro Líquido
-6.0%
Sua barra de distintivos está vazia — fixe uma métrica em qualquer lugar desta página.
CRL Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$290.19
Capitalização de Mercado (MRQ)
$13.85B
P/E (TTM)
-60.5
EPS (TTM)
$-4.80
Receita (TTM)
$4.00B
ROE (TTM)
-7.7%
Dívida/Capital (MRQ)
0.0
Intervalo 52 Semanas
$146–$303
CRL Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
intervalo
barras
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
Sobre Charles River Laboratories International, Inc. Common Stock Visão geral da empresa da Wikipedia
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients.
Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
History
Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.
In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.
The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.
Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.
In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.
In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.
In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.
Acquisitions
In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.
Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.
In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.
In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.
From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.
The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.
In July 2015, the company announced it would acquire Celsis International for $212 million.
In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.
In August 2017, the business announced it would acquire Brains On-Line.
In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.
In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.
In August 2020, the company announced it would acquire Cellero for $38 million in cash.
In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.
In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.
In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.
In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M.
In April 2022, the company announced it would acquire Explora BioLabs.
In January 2023, the business announced it would acquire SAMDI Tech, Inc.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
setorHealthcare
indústriaLife Sciences Tools & Services
funcionários18.300
paísUS
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita$4.02B2016-12-31 → 2025-12-27
EPS$-2.912016-12-31 → 2025-12-27
Fluxo de caixa livre$518M2016-12-31 → 2025-12-27
Margem líquida-6.0%2016-12-31 → 2025-12-27
Avaliação e Proporções
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | CRL | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E (TTM) | -60.5média 5A ≈191.6 | ≈191.6 | · | · | |
| P/S (TTM) | 3.5média 5A ≈3.2 | ≈3.2 | 4.9 | Subvalorizado | |
| P/B (MRQ) | 4.9média 5A ≈4.1 | ≈4.1 | 3.6 | Valor justo | |
| EV / EBITDA | 32.8média 5A ≈16.9 | ≈16.9 | 25.4 | Subvalorizado | |
| Preço / FCF (TTM) | 37.4média 5A ≈28.8 | ≈28.8 | · | · | |
| Preço / Fluxo de Caixa (TTM) | 23.8média 5A ≈17.3 | ≈17.3 | 26.2 | Subvalorizado | |
| EV / Revenue (EV / Receita) | 3.5média 5A ≈3.1 | ≈3.1 | · | · | |
| EV / FCF | 27.1média 5A ≈28.3 | ≈28.3 | · | · | |
| Preço / Valor Patrimonial Tangível (MRQ) | 5.4 | · | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | CRL | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Margem Operacional (TTM) | 2.3%média 5A ≈10.8% | ≈10.8% | 12.1% | Em linha | |
| Margem EBITDA (TTM) | 9.7%média 5A ≈19.2% | ≈19.2% | 14.8% | Primeira linha | |
| Pretax Margin (Margem de Impostos Pré-Tributação) | -2.5%média 5A ≈8.6% | ≈8.6% | 12.4% | Fraco | |
| Margem de Lucro Líquido (TTM) | -6.0%média 5A ≈6.3% | ≈6.3% | 10.8% | Fraco | |
| ROA (TTM) | -3.2%média 5A ≈3.4% | ≈3.4% | 2.0% | Fraco | |
| ROE (TTM) | -7.7%média 5A ≈9.0% | ≈9.0% | 3.3% | Fraco | |
| ROIC | 1.1%média 5A ≈10.7% | ≈10.7% | 3.0% | Fraco |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | CRL | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido (MRQ) | 0.0média 5A ≈0.0 | ≈0.0 | 0.1 | Baixa dívida | |
| Índice de liquidez corrente (MRQ) | 1.3média 5A ≈1.4 | ≈1.4 | 1.8 | Baixa liquidez | |
| Quick Ratio (Índice de Liquidez Seca) | 0.8média 5A ≈0.9 | ≈0.9 | 1.2 | Baixa liquidez |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | CRL | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | -0.85%média 5A ≈6.9% | ≈6.9% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | 0.33%média 5A ≈5.7% | ≈5.7% | · | · | |
| Revenue CAGR 5Y (CAGR Receita 5A) | 6.6% | · | · | · | |
| EPS YoY | -97.8%média 5A ≈-17.6% | ≈-17.6% | · | · | |
| Net Income YoY (Lucro Líquido Ano a Ano) | -95.3%média 5A ≈-16.5% | ≈-16.5% | · | · | |
| EPS CAGR 3Y (CAGR de LPA 3A) | -70.3% | · | · | · | |
| Net Income CAGR 3Y (CAGR de Lucro Líquido 3A) | -61.6% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | CRL | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 0.5média 5A ≈0.5 | ≈0.5 | 0.5 | Em linha | |
| Receivables Turnover (Giro de Contas a Receber) | 5.6média 5A ≈5.5 | ≈5.5 | 5.6 | Em linha | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$219.4K | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
8.9%
Próximo relatório
Nov 03, 2026
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 12, 2026 | $3.02 | $2.76 | 9.2% |
| 31 de Março de 2026 | $2.06 | $1.96 | 5.0% | |
| 31 de Dezembro de 2025 | $2.39 | $2.37 | 0.98% | |
| 30 de Setembro de 2025 | $2.43 | $2.36 | 2.9% | |
| 30 de Junho de 2025 | $3.12 | $2.52 | 23.7% | |
| 31 de Março de 2025 | $2.34 | $2.10 | 11.4% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $290M | $277M | $264M | $266M | |
| SG&A Expense | $743M | $751M | $748M | $665M | $620M | $529M | $518M | $444M | $371M | $365M | $300M | $269M | |
| Operating Income | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | |
| Interest Expense | · | · | $137M | $59M | $74M | $86M | $61M | $64M | $30M | $28M | $15M | $12M | |
| Interest Income | $5M | $9M | $5M | $780.0K | $652.0K | $834.0K | $2M | $812.0K | $690.0K | $1M | $1M | $1M | |
| Other Non-op | $-23M | $-17M | $96M | $31M | $-36M | $100M | $12M | $13M | $38M | $12M | $3M | $11M | |
| Pretax Income | $-100M | $93M | $581M | $623M | $481M | $447M | $304M | $282M | $297M | $223M | $195M | $178M | |
| Income Tax | $43M | $68M | $101M | $130M | $82M | $82M | $50M | $54M | $171M | $67M | $43M | $48M | |
| Net Income | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 | $3.21 | $2.72 | |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | |
| Shares (Basic) | 49,564,000 | 51,380,000 | 51,227,000 | 50,812,000 | 50,293,000 | 49,550,000 | 48,730,000 | 47,947,000 | 47,481,000 | 47,014,000 | 46,496,000 | 46,627,000 | |
| Shares (Diluted) | 49,564,000 | 51,628,000 | 51,451,000 | 51,301,000 | 51,425,000 | 50,611,000 | 49,693,000 | 49,018,000 | 48,564,000 | 47,958,000 | 47,634,000 | 47,558,000 | |
| EBITDA | $428M | $589M | $931M | $955M | $855M | $668M | $549M | $493M | $419M | $364M | $301M | $274M |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $214M | $195M | $277M | $234M | $241M | $228M | $238M | $195M | $164M | $118M | $118M | $160M | |
| Short-term Investments | · | · | · | · | $1M | $1M | $941.0K | $885.0K | $28M | $4M | $21M | · | |
| Receivables | $709M | $721M | $780M | $752M | $643M | $618M | $514M | $472M | $430M | $364M | $270M | $258M | |
| Inventory | $299M | $279M | $380M | $256M | $199M | $186M | $161M | $128M | $115M | $96M | $94M | $89M | |
| Prepaid Expense | $129M | $106M | $83M | $108M | $97M | $73M | $56M | $49M | $81M | $45M | $47M | $45M | |
| Other Current Assets | · | · | · | · | · | $0 | $300.0K | $300.0K | $0 | $45M | $47M | $73M | |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $898M | $827M | $657M | $559M | $579M | |
| PP&E (Net) | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $933M | $782M | $756M | $678M | $677M | |
| PP&E (Gross) | $3.19B | $3.06B | $2.98B | $2.63B | $2.39B | $2.21B | $2.02B | $1.81B | $1.58B | $1.46B | $1.32B | $1.33B | |
| Accum. Depreciation | $1.54B | $1.45B | $1.34B | $1.16B | $1.10B | $1.09B | $978M | $874M | $801M | $706M | $645M | $655M | |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $805M | $788M | $439M | $321M | |
| Intangibles | $340M | $723M | $864M | $955M | $1.06B | $788M | $689M | $611M | $370M | $394M | $281M | $281M | |
| Other Non-current Assets | $293M | $278M | $309M | $148M | $152M | $353M | $213M | $144M | $124M | $88M | $72M | $73M | |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Accounts Payable | $149M | $140M | $169M | $206M | $198M | $122M | $111M | $66M | $78M | $68M | $37M | $34M | |
| Accrued Liabilities | $270M | $232M | $228M | $220M | $229M | $150M | $139M | $107M | $90M | $84M | $89M | $67M | |
| Current Liabilities | $1.12B | $994M | $1.06B | $1.09B | $1.03B | $840M | $710M | $558M | $464M | $430M | $312M | $295M | |
| Capital Leases | $434M | $484M | $419M | $390M | $253M | $156M | $116M | · | · | · | · | · | |
| Deferred Tax | $95M | $107M | $191M | $216M | $240M | $217M | $167M | $144M | $90M | $56M | $48M | $23M | |
| Other Non-current Liabilities | $138M | $195M | $223M | $175M | $243M | $205M | $183M | $179M | $195M | $159M | $89M | $100M | |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B | $1.30B | $1.17B | |
| Long-term Debt | · | · | · | · | · | · | · | $1.61B | $1.09B | $1.18B | $814M | $717M | |
| Total Debt | $166.0K | $155.0K | $3M | $1M | $101.0K | $47M | $36M | $1.65B | $1.12B | $1.21B | $836M | $754M | |
| Common Stock | $492.0K | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K | $489.0K | $482.0K | $875.0K | $863.0K | $855.0K | $845.0K | |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $981M | $625M | $280M | $42M | $289M | $165M | $11M | $-139M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.0K | $1.66B | $1.55B | $1.54B | $1.42B | |
| AOCI | $-172M | $-317M | $-196M | $-262M | $-165M | $-139M | $-178M | $-173M | $-145M | $-254M | $-136M | $-74M | |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $837M | $733M | $672M | |
| Liabilities + Equity | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Shares Outstanding | 49,217,000 | 51,141,000 | 51,338,000 | 50,944,000 | 50,480,000 | 49,767,000 | 48,936,000 | 48,209,000 | 47,402,000 | 47,363,000 | 46,698,000 | 47,327,000 |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $403M | $362M | $314M | $304M | $266M | $235M | $198M | $162M | $131M | $127M | $95M | $96M | |
| Stock-based Comp | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | |
| Deferred Tax | $-75M | $-67M | $-51M | $-33M | $-20M | $2M | $-21M | $-10M | $28M | $3M | $4M | $9M | |
| Amort. of Intangibles | $179M | $138M | $137M | $147M | $125M | $112M | $90M | $65M | $41M | $42M | $24M | $26M | |
| Restructuring | $100M | $107M | $30M | $8M | $7M | $13M | $14M | $10M | $5M | $18M | $8M | $8M | |
| Other Non-cash | $483M | $348M | $-126M | $-211M | $53M | $-111M | $-5M | $16M | $-8M | $-28M | $-395.0K | · | |
| Operating Cash Flow | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | $307M | $252M | |
| CapEx | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | |
| Investing Cash Flow | $-209M | $-245M | $-563M | $-608M | $-1.44B | $-602M | $-682M | $-955M | $-73M | $-693M | · | · | |
| Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | $237M | $1.04B | · | · | |
| Net Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | · | · | · | · | |
| Stock Repurchased | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | |
| Net Stock Activity | $-361M | $-119M | $-24M | $-39M | $-41M | $-24M | $-18M | $-14M | $-107M | $-12M | $-117M | $-122M | |
| Financing Cash Flow | $-537M | $-551M | $-86M | $-42M | $673M | $47M | $232M | $558M | $-208M | $381M | · | · | |
| Net Change in Cash | $10M | $-79M | $43M | $-5M | $13M | $-7M | $43M | $31M | $46M | $-69.0K | $-43M | $4M | |
| Taxes Paid | $120M | $126M | $90M | $76M | $75M | $60M | $54M | $68M | · | · | · | · | |
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $245M | $225M | $195M | |
| Levered FCF | · | · | $252M | $248M | $471M | $309M | $290M | $250M | $223M | $226M | $213M | $186M |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | |
| Net Margin | -3.6% | 0.55% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | · | |
| Pretax Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | 15.3% | 11.6% | 12.4% | 16.0% | 13.3% | 14.3% | 13.7% | |
| EBITDA Margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% | 20.9% | 21.8% | 22.5% | 21.6% | 22.1% | 21.1% | |
| ROA | -2.0% | 0.28% | 6.0% | 6.7% | 6.2% | 7.1% | 5.9% | 6.7% | 4.4% | 6.5% | 7.6% | · | |
| ROE | -4.4% | 0.63% | 14.4% | 17.6% | 16.8% | 19.4% | 17.1% | 19.2% | 13.1% | 19.7% | 21.2% | · | |
| ROIC | 1.1% | 1.8% | 14.2% | 17.3% | 19.3% | 16.4% | 17.6% | 9.0% | 5.6% | 8.1% | 10.2% | 9.1% |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 | 1.4 | 1.4 | 1.6 | 1.8 | 1.5 | 1.8 | 2.0 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.1 | 1.2 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.1 | 1.4 | 1.1 | 1.1 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 1.2 | 1.0 | 1.4 | 1.1 | 1.1 | |
| Interest Coverage | · | · | 4.5 | 11.0 | 8.0 | 5.0 | 5.8 | 5.2 | 9.7 | 8.6 | 13.7 | 14.9 |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 2.7 | 2.9 | 2.9 | 3.0 | |
| Receivables Turnover | 5.6 | 5.4 | 5.4 | 5.7 | 5.6 | 5.2 | 5.3 | 5.0 | 4.7 | 5.3 | 5.2 | 5.4 |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $64.30 | $67.69 | $70.06 | $58.42 | $50.21 | $42.49 | $33.40 | $27.33 | $22.05 | $17.67 | $15.70 | $14.20 | |
| Revenue / Share | $81.01 | $78.45 | $80.26 | $77.50 | $68.84 | $57.77 | $52.75 | $46.23 | $38.25 | $35.06 | · | · | |
| Cash Flow / Share | $14.88 | $14.23 | $13.29 | $12.08 | $14.79 | $10.80 | $9.68 | $9.00 | $6.55 | $6.26 | · | · | |
| Cash / Share | $4.34 | $3.81 | $5.39 | $4.59 | $4.78 | $4.59 | $4.86 | $4.05 | $3.46 | $2.48 | $2.53 | $3.38 | |
| EPS (TTM) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.85% | -1.9% | 3.9% | 12.3% | 21.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.33% | 4.6% | 12.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | -97.8% | -2.7% | 24.7% | 5.6% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -70.3% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | -95.3% | -2.4% | 24.4% | 7.3% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -61.6% | 9.2% | · | · | · | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Net Income TTM | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| Market Cap | $10.02B | $9.52B | $12.14B | $11.10B | $18.64B | $12.53B | $7.43B | $5.39B | $5.19B | $3.61B | $3.74B | $3.04B | |
| Enterprise Value | $9.81B | $9.33B | $11.86B | $10.87B | $18.40B | $12.34B | $7.23B | $6.84B | $6.12B | $4.70B | $4.46B | $3.64B | |
| P/E | -70.0 | 930.8 | 25.6 | 23.0 | 48.6 | 35.0 | 30.0 | 24.2 | 43.1 | 23.6 | 25.6 | 24.2 | |
| P/S | 2.5 | 2.4 | 2.9 | 2.8 | 5.3 | 4.3 | 2.8 | 2.4 | 2.8 | 2.1 | 2.7 | 2.3 | |
| P/B | 3.2 | 2.8 | 3.4 | 3.7 | 7.4 | 5.9 | 4.5 | 4.1 | 5.0 | 4.3 | 5.1 | 4.5 | |
| P / Tangible Book | 166.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 13.6 | 13.0 | 17.7 | 17.9 | 24.5 | 22.9 | 15.5 | 12.2 | 16.3 | 12.0 | 13.0 | 12.1 | |
| P / FCF | 19.3 | 19.0 | 33.2 | 37.6 | 35.0 | 33.0 | 21.8 | 17.9 | 22.0 | 14.7 | 16.6 | 15.6 | |
| EV / EBITDA | 22.9 | 15.8 | 12.7 | 11.4 | 21.5 | 18.5 | 13.2 | 13.9 | 14.6 | 12.9 | 14.8 | 13.3 | |
| EV / FCF | 18.9 | 18.6 | 32.5 | 36.9 | 34.6 | 32.5 | 21.2 | 22.7 | 26.0 | 19.2 | 19.8 | 18.6 | |
| EV / Revenue | 2.4 | 2.3 | 2.9 | 2.7 | 5.2 | 4.2 | 2.8 | 3.0 | 3.3 | 2.8 | 3.3 | 2.8 | |
| Earnings Yield | -1.4% | 0.11% | 3.9% | 4.3% | 2.1% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% | 3.9% | 4.1% |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $996M | $994M | $1.00B | $1.03B | $984M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.03B | $1.10B | $989M | |
| Cost of Revenue | · | · | · | · | · | · | · | $661M | $672M | $667M | · | $665M | $652M | · | · | |
| SG&A Expense | $229M | $159M | $196M | $178M | $192M | $178M | $196M | $199M | $170M | $186M | $197M | $176M | $175M | $200M | $184M | |
| Operating Income | $120M | $120M | $-283M | $134M | $100M | $75M | $-168M | $117M | $152M | $126M | $133M | $152M | $168M | $164M | $151M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $34M | $34M | · | $11M | |
| Interest Income | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M | $2M | $1M | $806.0K | $343.0K | $122.0K | |
| Other Non-op | $-37M | $-124M | $12M | $-23M | $154.0K | $-12M | $-23M | $3M | $-2M | $6M | $108M | $-6M | $-3M | $116M | $-17M | |
| Income Tax | $54M | $-15M | $-18M | $32M | $19M | $10M | $-3M | $21M | $25M | $25M | $20M | $25M | $27M | $56M | $25M | |
| Net Income | $-1M | $-15M | $-277M | $54M | $52M | $25M | $-214M | $70M | $94M | $73M | $187M | $87M | $103M | $187M | $96M | |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 | $1.75 | $1.31 | $3.65 | $1.70 | $2.02 | $3.68 | $1.90 | |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 | $1.74 | $1.30 | $3.64 | $1.69 | $2.01 | $3.66 | $1.88 | |
| Shares (Basic) | 48,021,000 | 48,951,000 | · | 49,213,000 | 49,149,000 | 50,677,000 | · | 51,394,000 | 51,551,000 | 51,437,000 | · | 51,283,000 | 51,097,000 | · | 50,870,000 | |
| Shares (Diluted) | 48,021,000 | 48,951,000 | · | 49,426,000 | 49,316,000 | 50,853,000 | · | 51,583,000 | 51,846,000 | 51,842,000 | · | 51,607,000 | 51,428,000 | · | 51,283,000 | |
| EBITDA | $187M | $187M | · | $219M | $220M | $195M | · | $206M | $238M | $211M | · | $230M | $245M | · | $226M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192M | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M | $327M | · | $157M | $202M | · | $194M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Receivables | $712M | $700M | $709M | $734M | $768M | $757M | $721M | $754M | $762M | $787M | · | $799M | $788M | · | $771M | |
| Inventory | $346M | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M | $361M | · | $293M | $263M | · | $262M | |
| Prepaid Expense | $179M | $135M | $129M | $166M | $130M | $100M | $106M | $102M | $111M | $99M | · | $93M | $92M | · | $97M | |
| Current Assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | · | $1.44B | $1.45B | · | $1.42B | |
| PP&E (Net) | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $2.96B | $2.94B | $3.19B | $3.09B | $3.10B | $3.05B | $3.06B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $1.46B | $1.43B | $1.54B | $1.50B | $1.50B | $1.46B | $1.45B | · | · | · | · | · | · | · | · | |
| Goodwill | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | · | $2.88B | $2.90B | · | $2.78B | |
| Intangibles | $253M | $249M | $340M | $571M | $602M | $656M | $723M | $778M | $800M | $828M | · | $886M | $958M | · | $968M | |
| Other Non-current Assets | $588M | $826M | $293M | $291M | $296M | $294M | $278M | $307M | $301M | $303M | · | $155M | $154M | · | $430M | |
| Total Assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Accounts Payable | $141M | $134M | $149M | $170M | $146M | $149M | $140M | $136M | $133M | $130M | · | $136M | $120M | · | $182M | |
| Accrued Liabilities | $380M | $372M | $270M | $229M | $232M | $242M | $232M | $208M | $192M | $191M | · | $198M | $221M | · | $197M | |
| Current Liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994M | $1.01B | $948M | $955M | · | $994M | $981M | · | $1.01B | |
| Capital Leases | $408M | $393M | $434M | $443M | $454M | $475M | $484M | $433M | $429M | $418M | · | $390M | $418M | · | $369M | |
| Deferred Tax | $79M | $81M | $95M | $123M | $109M | $107M | $107M | $168M | $165M | $180M | · | $185M | $212M | · | $196M | |
| Other Non-current Liabilities | $403M | $511M | $138M | $189M | $185M | $196M | $195M | $237M | $225M | $235M | · | $173M | $187M | · | $195M | |
| Total Liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | · | $4.26B | $4.54B | · | $4.71B | |
| Total Debt | $5M | $7M | · | $54.0K | $98.0K | $121.0K | · | $157.0K | $435.0K | $459.0K | · | $797.0K | · | · | $0 | |
| Common Stock | $496.0K | $493.0K | $492.0K | $514.0K | $513.0K | $512.0K | $511.0K | $517.0K | $517.0K | $515.0K | · | $514.0K | $512.0K | · | $510.0K | |
| Retained Earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | · | $1.72B | $1.54B | · | $1.28B | |
| Treasury Stock | $323M | $210M | $0 | $363M | $363M | $357M | $0 | $120M | $18M | $9M | · | $24M | $19M | · | $38M | |
| AOCI | $-196M | $-191M | $-172M | $-192M | $-166M | $-265M | $-317M | $-193M | $-270M | $-250M | · | $-268M | $-239M | · | $-396M | |
| Stockholders' Equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | · | $3.31B | $3.11B | · | $2.63B | |
| Liabilities + Equity | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Shares Outstanding | 47,728,000 | 48,167,000 | 49,217,000 | 49,215,000 | 49,209,000 | 49,115,000 | 51,141,000 | 51,134,000 | 51,613,000 | 51,510,000 | · | 51,296,000 | 51,182,000 | 50,944,000 | 50,877,000 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $67M | $67M | $78M | $85M | $120M | $120M | $102M | $88M | $86M | $85M | $81M | $79M | $77M | $78M | $75M | |
| Stock-based Comp | $20M | $22M | $18M | $23M | $17M | $13M | $17M | $19M | $17M | $17M | $20M | $23M | $13M | $22M | $22M | |
| Amort. of Intangibles | $15M | $15M | $21M | $27M | $65M | $65M | $41M | $32M | $32M | $33M | $34M | $34M | $35M | $35M | $36M | |
| Restructuring | $23M | $32M | $26M | $17M | $32M | $24M | $41M | $31M | $18M | $17M | $8M | $15M | $3M | $4M | $1M | |
| Other Non-cash | · | $-34M | · | · | · | $13M | · | · | · | $-45M | · | · | $-84M | · | · | |
| Operating Cash Flow | $180M | $41M | $148M | $214M | $205M | $172M | $159M | $252M | $194M | $130M | $221M | $205M | $109M | $235M | $133M | |
| CapEx | $31M | $56M | $89M | $36M | $35M | $59M | $76M | $39M | $39M | $79M | $78M | $66M | $107M | $89M | $72M | |
| Investing Cash Flow | $28M | $-408M | $-93M | $-34M | $-37M | $-45M | $-76M | $-21M | $-62M | $-86M | $-238M | $-80M | $-169M | $44M | $-92M | |
| Debt Issued | $353M | $912M | $157M | $107M | $547M | $416M | $105M | $236M | $440M | $301M | $443M | $51M | $192M | $154M | $618M | |
| Net Debt Issued | · | $912M | · | · | · | $416M | · | · | · | $301M | · | · | $192M | · | · | |
| Stock Repurchased | $116M | $208M | $96.0K | $93.0K | $7M | $353M | $124.0K | $101M | $9M | $9M | $139.0K | $38.0K | $19M | $159.0K | $24.0K | |
| Net Stock Activity | · | $-208M | · | · | · | $-353M | · | · | · | $-9M | · | · | $-19M | · | · | |
| Financing Cash Flow | $-165M | $348M | $-52M | $-153M | $-227M | $-105M | $-76M | $-208M | $-286M | $18M | $124M | $-163M | $25M | $-249M | $-52M | |
| Net Change in Cash | $42M | $-18M | $7M | $24M | $-47M | $26M | $-6M | $31M | $-158M | $54M | $119M | $-43M | $-32M | $45M | $-11M | |
| Taxes Paid | $16M | $2M | $27M | $19M | $57M | $17M | $31M | $23M | $53M | $19M | $15M | $14M | $14M | · | · | |
| Free Cash Flow | · | $-15M | · | · | · | $112M | · | · | · | $51M | · | · | $3M | · | · |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 12.0% | · | 13.3% | 9.7% | 7.6% | · | 11.6% | 14.8% | 12.4% | · | 14.8% | 16.3% | · | 15.3% | |
| Net Margin | -0.15% | -1.5% | · | 5.4% | 5.1% | 2.6% | · | 6.9% | 9.2% | 7.2% | · | 8.5% | 10.0% | · | 9.8% | |
| EBITDA Margin | 18.6% | 18.8% | · | 21.8% | 21.3% | 19.8% | · | 20.4% | 23.2% | 20.9% | · | 22.4% | 23.8% | · | 22.8% | |
| ROA | -0.02% | -0.19% | · | 0.70% | 0.67% | 0.32% | · | 0.89% | 1.2% | 0.92% | · | 1.2% | · | · | 1.3% | |
| ROE | -0.05% | -0.48% | · | 1.5% | 1.5% | 0.75% | · | 2.0% | 2.7% | 2.2% | · | 2.9% | · | · | 3.8% |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 1.5 | · | · | 1.4 | |
| Quick Ratio | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.2 | · | 1.0 | · | · | 1.0 | |
| Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.6 | · | 4.5 | 4.9 | · | 13.3 |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 2.1 | 2.1 | 2.1 | · | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · | 1.4 |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $59.50 | $61.05 | · | $69.20 | $68.14 | $65.04 | · | $73.97 | $72.13 | $70.67 | · | $64.45 | · | · | $51.63 | |
| Revenue / Share | $20.91 | $20.34 | · | $20.33 | $20.93 | $19.35 | · | $19.58 | $19.79 | $19.51 | · | $19.89 | $20.02 | · | $19.29 | |
| Cash Flow / Share | · | $0.84 | · | · | · | $3.38 | · | · | · | $2.51 | · | · | $2.13 | · | · | |
| Cash / Share | $4.02 | $3.98 | · | $4.21 | $3.72 | $4.67 | · | $4.11 | $3.47 | $6.35 | · | $3.06 | · | · | $3.81 | |
| EPS (TTM) | $-4.80 | $-3.71 | · | $-1.51 | $-1.28 | $-0.60 | · | $8.01 | $8.37 | $8.52 | · | $9.25 | $9.68 | · | $8.49 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.00B | $4.03B | · | $4.02B | $4.03B | $4.02B | · | $4.06B | $4.08B | $4.11B | · | $4.22B | $4.09B | · | $3.78B | |
| Net Income TTM | $-238M | $-185M | · | $-82M | $-67M | $-25M | · | $424M | $442M | $444M | · | $475M | $496M | · | $436M | |
| Market Cap | $10.30B | $7.67B | · | $7.31B | $7.38B | $7.64B | · | $10.14B | $10.66B | $13.96B | · | $10.05B | · | · | $9.54B | |
| Enterprise Value | $10.11B | $7.48B | · | $7.10B | $7.20B | $7.41B | · | $9.93B | $10.48B | $13.63B | · | $9.90B | · | · | $9.35B | |
| P/E | -44.9 | -42.9 | · | -98.4 | -117.2 | -259.2 | · | 24.8 | 24.7 | 31.8 | · | 21.2 | 20.8 | · | 22.1 | |
| P/S | 2.6 | 1.9 | · | 1.8 | 1.8 | 1.9 | · | 2.5 | 2.6 | 3.4 | · | 2.4 | 2.5 | · | 2.5 | |
| P/B | 3.6 | 2.6 | · | 2.1 | 2.2 | 2.4 | · | 2.7 | 2.9 | 3.8 | · | 3.0 | · | · | 3.6 | |
| P / Cash Flow | · | 186.6 | · | · | · | 44.5 | · | · | · | 107.5 | · | · | · | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.4 | 2.6 | 3.3 | · | 2.3 | 2.5 | · | 2.5 | |
| Earnings Yield | -2.2% | -2.3% | · | -1.0% | -0.85% | -0.39% | · | 4.0% | 4.0% | 3.1% | · | 4.7% | 4.8% | · | 4.5% |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Receita | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Margem Operacional % | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% |
| Lucro líquido | $-144M | $22M | $475M | $486M | $391M |
| EPS Diluído | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
| Métrica | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Índice de liquidez corrente | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 |
| Índice de Liquidez Seca | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |
| Métrica | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $518M | $502M | $365M | $295M | $532M |
Investidores institucionais (13F) 607 declarantes · $13.6B total · Em 30 de Setembro de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Detentores
607
Valor detido
$13.6B
Novas posições
74
Posições encerradas
62
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 74 (-17 vs trimestre anterior) | 62 (-19 vs trimestre anterior) | 193 (0 vs trimestre anterior) | 204 (+13 vs trimestre anterior) | +2.8M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1.174.373.670 | 5.887.175 | 8,65% | Ações |
| FMR LLC | $961.533.236 | 4.239.752 | 7,09% | Ações |
| BlackRock, Inc. | $861.475.349 | 3.798.560 | 6,35% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $714.227.026 | 3.149.288 | 5,26% | Ações |
| Invesco Ltd. | $676.919.391 | 2.984.785 | 4,99% | Ações |
| HARRIS ASSOCIATES L P | $508.269.048 | 2.241.144 | 3,75% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501.427.927 | 2.210.979 | 3,70% | Ações |
| Allspring Global Investments Holdings, LLC | $436.473.035 | 1.905.247 | 3,22% | Ações |
| STATE STREET CORP | $422.800.968 | 1.864.284 | 3,12% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $373.848.597 | 1.648.450 | 2,76% | Ações |
| ARIEL INVESTMENTS, LLC | $341.587.697 | 1.506.185 | 2,52% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $295.598.099 | 1.305.738 | 2,18% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $292.210.525 | 1.288.463 | 2,15% | Ações |
| CITADEL ADVISORS LLC | $270.696.771 | 1.193.601 | 1,99% | Ações |
| BANK OF AMERICA CORP /DE/ | $265.930.779 | 1.172.586 | 1,96% | Ações |
| EARNEST PARTNERS LLC | $254.007.295 | 1.120.011 | 1,87% | Ações |
| AMERIPRISE FINANCIAL INC | $199.834.979 | 881.189 | 1,47% | Ações |
| NEUBERGER BERMAN GROUP LLC | $195.633.630 | 862.704 | 1,44% | Ações |
| SEI INVESTMENTS CO | $184.499.540 | 813.530 | 1,36% | Ações |
| MORGAN STANLEY | $181.542.851 | 800.487 | 1,34% | Ações |
| Clearbridge Investments, LLC | $177.185.527 | 781.276 | 1,31% | Ações |
| COOKE & BIELER LP | $171.369.328 | 755.630 | 1,26% | Ações |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $157.642.604 | 682.173 | 1,16% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $150.762.735 | 664.768 | 1,11% | Ações |
| UBS Group AG | $146.675.752 | 646.747 | 1,08% | Ações |
| GOLDMAN SACHS GROUP INC | $145.100.822 | 639.803 | 1,07% | Ações |
| MILLENNIUM MANAGEMENT LLC | $110.324.717 | 486.462 | 0,81% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $106.061.291 | 467.663 | 0,78% | Ações |
| BANK OF MONTREAL /CAN/ | $104.270.783 | 459.768 | 0,77% | Ações |
| NORTHERN TRUST CORP | $101.169.205 | 446.092 | 0,75% | Ações |
| Gotham Asset Management, LLC | $98.233.181 | 433.146 | 0,72% | Ações |
| Amundi | $93.528.650 | 412.402 | 0,69% | Ações |
| NORGES BANK | $83.921.372 | 370.040 | 0,62% | Ações |
| MARSHALL WACE, LLP | $77.787.835 | 342.995 | 0,57% | Ações |
| Iron Triangle Partners LP | $75.748.141 | 379.728 | 0,56% | Ações |
| CITIGROUP INC | $71.714.853 | 316.217 | 0,53% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $69.108.583 | 304.725 | 0,51% | Ações |
| Bank of New York Mellon Corp | $69.054.385 | 304.486 | 0,51% | Ações |
| Boston Trust Walden Corp | $65.523.486 | 288.917 | 0,48% | Ações |
| JPMORGAN CHASE & CO | $65.085.033 | 286.317 | 0,48% | Ações |
| ALLIANCEBERNSTEIN L.P. | $64.615.913 | 374.585 | 0,48% | Ações |
| SNYDER CAPITAL MANAGEMENT L P | $63.899.443 | 281.756 | 0,47% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $63.174.169 | 278.558 | 0,47% | Ações |
| DEUTSCHE BANK AG\ | $62.723.084 | 276.569 | 0,46% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $61.384.115 | 270.665 | 0,45% | Ações |
| PRIMECAP MANAGEMENT CO/CA/ | $60.523.448 | 266.870 | 0,45% | Ações |
| RAYMOND JAMES FINANCIAL INC | $58.234.910 | 256.779 | 0,43% | Ações |
| Meridiem Capital Partners LP | $56.012.367 | 246.979 | 0,41% | Ações |
| Alyeska Investment Group, L.P. | $53.295.650 | 235.000 | 0,39% | Ações |
| LOOMIS SAYLES & CO L P | $50.725.593 | 223.668 | 0,37% | Ações |
Ativistas e proprietários de 5%+ 6 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| JANA PARTNERS LLC ×4 declarações | 4 de Agosto de 2011 | · | Declaração inicial | · | SEC |
| Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 declarações | 9 de Fevereiro de 2011 | · | Declaração inicial | · | SEC |
| Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 declarações | 7 de Dezembro de 2010 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada | 16 de Junho de 2010 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada | 7 de Junho de 2010 | · | Declaração inicial | Investimento passivo | SEC |
| Charles River Laboratories International, Inc. IRS No. 061397316 | 5 de Maio de 2010 | · | Declaração inicial | Campanha no conselho | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 57 insiders · 23 diretores · 29 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Birgit Girshick | Chief Executive Officer | 19 de Agosto de 2026 G | 35.485 | 0 | 1 | $-1.819.350 |
| Glenn Coleman | EVP & Chief Financial Officer | 30 de Setembro de 2026 P | 27.762 | 1 | 0 | $2.974 |
| Flavia Pease | Corporate Executive VP & CFO | 31 de Maio de 2025 F | 17.297 | 0 | 0 | $0 |
| David Ross Smith | Corporate Executive VP & CFO | 3 de Março de 2022 M | 25.819 | 0 | 0 | $0 |
| Davide Molho | President & COO | 24 de Julho de 2018 M | 17.155 | 0 | 0 | $0 |
| Shannon M Parisotto | CEVP, Disc & Safety Assessment | 19 de Agosto de 2026 M | 4.807 | 0 | 3 | $-2.965.466 |
| Mark Mintz | EVP, Chief Information Officer | 31 de Maio de 2026 F | 9.546 | 0 | 0 | $0 |
| William D Barbo | Corporate Executive VP & CCO | 7 de Novembro de 2024 G | 23.337 | 0 | 0 | $0 |
| John W Kuo | CEVP General Counsel & CCO | 1 de Junho de 2020 A | 3.171 | 0 | 0 | $0 |
| David P Johst | Corporate Executive VP | 29 de Maio de 2020 A | 224.478 | 0 | 0 | $0 |
| John J Crowley | SVP, Chief Accounting Officer | 1 de Outubro de 2016 F | 5.599 | 0 | 0 | $0 |
| Nancy Gillett | Corporate Executive VP | 2 de Março de 2016 S | 11.034 | 0 | 0 | $0 |
| Jorg Geller | Corporate Executive VP | 25 de Fevereiro de 2015 M | 14.094 | 0 | 0 | $0 |
| RENAUD REAL H | Corp. Executive VP | 11 de Agosto de 2010 F | 74.390 | 0 | 0 | $0 |
| Christopher Berthoux | Executive Vice President | 26 de Fevereiro de 2010 A | 31.897 | 0 | 0 | $0 |
| Joanne P Acford | Corp. Sr VP, GC and Corp. Sec | 11 de Agosto de 2007 F | 37.109 | 0 | 0 | $0 |
| David J Elliott | Officer | 29 de Junho de 2007 M | 11.750 | 0 | 0 | $0 |
| Cheri L Walker | Corporate Senior VP | 1 de Maio de 2007 A | 6.262 | 0 | 0 | $0 |
| Stephanie B Wells | Senior Vice President | 2 de Abril de 2007 A | 11.500 | 0 | 0 | $0 |
| Nicholas Ventresca | Senior Vice President | 2 de Abril de 2007 F | 12.713 | 0 | 0 | $0 |
| John C Ho | Senior Vice President | 23 de Fevereiro de 2007 A | 12.710 | 0 | 0 | $0 |
| Brian Bathgate | Corporate Vice President | 27 de Fevereiro de 2006 S | 16.134 | 0 | 0 | $0 |
| Alastair Stuart Mcewan | Corporate VP | 23 de Dezembro de 2004 M | 8.000 | 0 | 0 | $0 |
| James C Foster | Conselheiro | 25 de Agosto de 2026 M | 31.596 | 0 | 3 | $-34.844.875 |
| Nancy C Andrews | Conselheiro | 18 de Agosto de 2026 M | 1.438 | 0 | 1 | $-163.443 |
| Steven Barg | Conselheiro | 2 de Junho de 2026 A | 3.287 | 0 | 0 | $0 |
| Reshema Kemps-Polanco | Conselheiro | 8 de Maio de 2026 A | 4.563 | 0 | 0 | $0 |
| George Llado | Conselheiro | 8 de Maio de 2026 A | 6.702 | 0 | 0 | $0 |
| Abraham Ceesay | Conselheiro | 8 de Maio de 2026 A | 2.384 | 0 | 0 | $0 |
| Mark J Enyedy | Conselheiro | 8 de Maio de 2026 A | 2.384 | 0 | 0 | $0 |
| Paul W Graves | Conselheiro | 8 de Maio de 2026 A | 2.384 | 0 | 0 | $0 |
| Craig B. Thompson | Conselheiro | 8 de Maio de 2026 A | 3.851 | 0 | 0 | $0 |
| Martin Mackay | Conselheiro | 8 de Maio de 2026 A | 17.137 | 0 | 0 | $0 |
| Virginia M Wilson | Conselheiro | 8 de Maio de 2026 A | 6.349 | 0 | 0 | $0 |
| George Massaro | Conselheiro | 15 de Maio de 2025 S | 5.575 | 0 | 0 | $0 |
| Richard F Wallman | Conselheiro | 7 de Novembro de 2024 S | 0 | 0 | 0 | $0 |
| Deborah Turner Kochevar | Conselheiro | 13 de Maio de 2024 A | 7.894 | 0 | 0 | $0 |
| Robert J Bertolini | Conselheiro | 13 de Maio de 2024 A | 32.802 | 0 | 0 | $0 |
| Richard C Reese | Conselheiro | 15 de Maio de 2023 A | 65.541 | 0 | 0 | $0 |
| George M Milne JR | Conselheiro | 7 de Maio de 2021 A | 29.079 | 0 | 0 | $0 |
| Stephen D Chubb | Conselheiro | 23 de Fevereiro de 2021 M | 40.529 | 0 | 0 | $0 |
| Jean-Paul Mangeolle | Conselheiro | 22 de Maio de 2019 A | 3.886 | 0 | 0 | $0 |
| William Waltrip | Conselheiro | 5 de Dezembro de 2012 S | 21.830 | 0 | 0 | $0 |
| Samuel O Thier MD | Conselheiro | 9 de Maio de 2012 A | 18.230 | 0 | 0 | $0 |
| Douglas E Rogers | Conselheiro | 7 de Maio de 2010 A | 12.859 | 0 | 0 | $0 |
| Nancy T Chang | Conselheiro | 7 de Maio de 2010 A | 31.010 | 0 | 0 | $0 |
| Linda Mcgoldrick | Conselheiro | 13 de Fevereiro de 2006 A | · | 0 | 0 | $0 |
| Walter S Nimmo | Conselheiro | 25 de Fevereiro de 2005 S | 149.447 | 0 | 0 | $0 |
| John Urquhart | Conselheiro | 17 de Fevereiro de 2005 A | 11.738 | 0 | 0 | $0 |
| Louise S Mccrary | Conselheiro | 17 de Fevereiro de 2005 A | · | 0 | 0 | $0 |
| Robert Cawthorn | Conselheiro | 2 de Junho de 2004 G | 278.600 | 0 | 0 | $0 |
| Joseph W Laplume | · | 10 de Agosto de 2026 G | 31.041 | 1 | 1 | $-61.124 |
| Victoria L Creamer | · | 6 de Agosto de 2026 M | 30.051 | 0 | 1 | $-1.083.030 |
| Michael Gunnar Knell | · | 6 de Agosto de 2026 M | 11.852 | 0 | 9 | $-1.730.250 |
| Thomas F Ackerman | · | 29 de Fevereiro de 2016 F | 111.346 | 0 | 0 | $0 |
| Dennis R Shaughnessy | · | 29 de Novembro de 2004 G | 35.511 | 0 | 0 | $0 |
| Michael F Ankcorn | · | 4 de Novembro de 2004 S | 0 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 106 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| EPSB · Harbor ETF Trust | 2,15% | 443 NS | 31 de Julho de 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,73% | 51.248 SH | 1 de Outubro de 2026 | Diário |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,71% | 5.092 NS | 31 de Julho de 2026 | N-PORT |
| EPSV · Harbor ETF Trust | 1,59% | 415 NS | 31 de Julho de 2026 | N-PORT |
| EPMV · Harbor ETF Trust | 1,44% | 291 NS | 31 de Julho de 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 1,09% | 4.303 NS | 31 de Julho de 2026 | N-PORT |
| IBB · iShares Trust | 0,96% | 363.741 SH | 11 de Setembro de 2026 | Diário |
| LSEQ · Harbor ETF Trust | 0,93% | 614 NS | 31 de Julho de 2026 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0,74% | 2.375 NS | 31 de Julho de 2026 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 0,69% | 22.191 SH | 1 de Outubro de 2026 | Diário |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,66% | 259 NS | 31 de Julho de 2026 | N-PORT |
| PALC · Pacer Funds Trust | 0,61% | 5.509 NS | 31 de Julho de 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,49% | 12.141 NS | 31 de Julho de 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,45% | 6.439 NS | 31 de Julho de 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,44% | 24.918 SH | 1 de Outubro de 2026 | Diário |
| FFSM · FIDELITY COVINGTON TRUST | 0,40% | 25.814 NS | 31 de Julho de 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,34% | 209.615 NS | 31 de Julho de 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,28% | 7.783 NS | 31 de Julho de 2026 | N-PORT |
| ESML · iShares Trust | 0,24% | 25.082 SH | 11 de Setembro de 2026 | Diário |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 20.898 NS | 31 de Julho de 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,24% | 25.378 NS | 31 de Julho de 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,23% | 13.626 NS | 31 de Julho de 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,23% | 701.498 SH | 19 de Agosto de 2026 | Diário |
| DFAS · Dimensional ETF Trust | 0,22% | 147.648 NS | 31 de Julho de 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0,22% | 702.813 SH | 1 de Outubro de 2026 | Diário |
| IYH · iShares Trust | 0,22% | 28.670 SH | 11 de Setembro de 2026 | Diário |
| SMMD · iShares Trust | 0,19% | 26.152 SH | 11 de Setembro de 2026 | Diário |
| IXJ · iShares Trust | 0,17% | 25.598 SH | 11 de Setembro de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,17% | 23.486 NS | 31 de Julho de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,16% | 148.331 SH | 19 de Agosto de 2026 | Diário |
| REVS · Columbia ETF Trust I | 0,15% | 2.111 NS | 31 de Julho de 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 3.646 NS | 31 de Julho de 2026 | N-PORT |
| WSML · iShares Trust | 0,14% | 6.080 SH | 11 de Setembro de 2026 | Diário |
| IWS · iShares Trust | 0,13% | 73.404 SH | 11 de Setembro de 2026 | Diário |
| VB · VANGUARD INDEX FUNDS | 0,13% | 1.102.914 SH | 19 de Agosto de 2026 | Diário |
| CURE · Direxion Shares ETF Trust | 0,13% | 947 NS | 31 de Julho de 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,12% | 42.976 NS | 31 de Julho de 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 2.764 SH | 1 de Outubro de 2026 | Diário |
| IEUS · iShares Trust | 0,10% | 5.579 SH | 11 de Setembro de 2026 | Diário |
| IWR · iShares Trust | 0,10% | 200.615 SH | 11 de Setembro de 2026 | Diário |
| RECS · Columbia ETF Trust I | 0,10% | 23.999 NS | 31 de Julho de 2026 | N-PORT |
| XOEF · iShares Trust | 0,07% | 61 SH | 11 de Setembro de 2026 | Diário |
| DFUV · Dimensional ETF Trust | 0,06% | 41.352 NS | 31 de Julho de 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,06% | 1.302 NS | 31 de Julho de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,05% | 106.991 NS | 31 de Julho de 2026 | N-PORT |
| IVE · iShares Trust | 0,04% | 79.930 SH | 11 de Setembro de 2026 | Diário |
| IUSV · iShares Trust | 0,04% | 42.675 SH | 11 de Setembro de 2026 | Diário |
| SCZ · iShares Trust | 0,04% | 171.786 SH | 11 de Setembro de 2026 | Diário |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,04% | 174.824 SH | 19 de Agosto de 2026 | Diário |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,04% | 11.139 SH | 19 de Agosto de 2026 | Diário |
| DCOR · Dimensional ETF Trust | 0,04% | 5.545 NS | 31 de Julho de 2026 | N-PORT |
| IWD · iShares Trust | 0,04% | 108.791 SH | 11 de Setembro de 2026 | Diário |
| CHRI · Global X Funds | 0,03% | 11 NS | 31 de Julho de 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 29.579 SH | 19 de Agosto de 2026 | Diário |
| PRF · Invesco Exchange-Traded Fund Trust | 0,03% | 9.073 SH | 1 de Outubro de 2026 | Diário |
| TOPC · iShares Trust | 0,03% | 32 SH | 11 de Setembro de 2026 | Diário |
| DFSU · Dimensional ETF Trust | 0,02% | 2.431 NS | 31 de Julho de 2026 | N-PORT |
| XVV · iShares Trust | 0,02% | 576 SH | 11 de Setembro de 2026 | Diário |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,02% | 1.252 SH | 1 de Outubro de 2026 | Diário |
| PBP · Invesco Exchange-Traded Fund Trust | 0,02% | 287 SH | 30 de Setembro de 2026 | Diário |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,02% | 7.028 SH | 1 de Outubro de 2026 | Diário |
| EGLE · Global X Funds | 0,02% | 2 NS | 31 de Julho de 2026 | N-PORT |
| IVV · iShares Trust | 0,02% | 607.129 SH | 11 de Setembro de 2026 | Diário |
| VOO · VANGUARD INDEX FUNDS | 0,02% | 1.250.774 SH | 19 de Agosto de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 1.530.468 SH | 19 de Agosto de 2026 | Diário |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,02% | 8.168 SH | 19 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 4.112 SH | 19 de Agosto de 2026 | Diário |
| ESGV · VANGUARD WORLD FUND | 0,02% | 11.106 SH | 19 de Agosto de 2026 | Diário |
| IWV · iShares Trust | 0,02% | 14.165 SH | 11 de Setembro de 2026 | Diário |
| IWB · iShares Trust | 0,02% | 33.863 SH | 11 de Setembro de 2026 | Diário |
| XRMI · Global X Funds | 0,02% | 41 NS | 31 de Julho de 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,02% | 9.979 NS | 31 de Julho de 2026 | N-PORT |
| XYLD · Global X Funds | 0,02% | 2.566 NS | 31 de Julho de 2026 | N-PORT |
| IYY · iShares Trust | 0,02% | 2.018 SH | 11 de Setembro de 2026 | Diário |
| ITOT · iShares Trust | 0,02% | 63.582 SH | 11 de Setembro de 2026 | Diário |
| PHDG · Invesco Actively Managed Exchange-T… | 0,02% | 38 SH | 1 de Outubro de 2026 | Diário |
| PTLC · Pacer Funds Trust | 0,02% | 2.492 NS | 31 de Julho de 2026 | N-PORT |
| TILT · FlexShares Trust | 0,02% | 1.620 NS | 31 de Julho de 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,02% | 14.645 NS | 31 de Julho de 2026 | N-PORT |
| XYLG · Global X Funds | 0,02% | 45 NS | 31 de Julho de 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,02% | 182 NS | 31 de Julho de 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,02% | 1.141 NS | 31 de Julho de 2026 | N-PORT |
| XTR · Global X Funds | 0,01% | 3 NS | 31 de Julho de 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0,01% | 332 NS | 31 de Julho de 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,01% | 3.766 NS | 31 de Julho de 2026 | N-PORT |
| IEUR · iShares Trust | 0,01% | 37.473 SH | 11 de Setembro de 2026 | Diário |
| XCLR · Global X Funds | 0,01% | 2 NS | 31 de Julho de 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,01% | 1.973 SH | 1 de Outubro de 2026 | Diário |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 110.946 SH | 19 de Agosto de 2026 | Diário |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 77.796 SH | 19 de Agosto de 2026 | Diário |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0,01% | 447.656 SH | 19 de Agosto de 2026 | Diário |
| IDEV · iShares Trust | 0,01% | 52.174 SH | 11 de Setembro de 2026 | Diário |
| IEFA · iShares Trust | 0,00% | 272.340 SH | 11 de Setembro de 2026 | Diário |
| NEAR · iShares U.S. ETF Trust | 0,00% | 140.000 SH | 9 de Setembro de 2026 | Diário |
| DFLV · Dimensional ETF Trust | 0,00% | 377 NS | 31 de Julho de 2026 | N-PORT |
| IXUS · iShares Trust | 0,00% | 22.623 SH | 11 de Setembro de 2026 | Diário |
| VXUS · VANGUARD STAR FUNDS | 0,00% | 664.961 SH | 19 de Agosto de 2026 | Diário |
| VSGX · VANGUARD WORLD FUND | 0,00% | 8.805 SH | 19 de Agosto de 2026 | Diário |
| VGHY · VANGUARD FIXED INCOME SECURITIES FU… | · | · | 15 de Julho de 2026 | Diário |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 de Julho de 2026 | Diário |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 15 de Julho de 2026 | Diário |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15 de Julho de 2026 | Diário |
| VGMS · VANGUARD MALVERN FUNDS | · | · | 15 de Julho de 2026 | Diário |
| ISCB · iShares Trust | · | 2.146 SH | 11 de Setembro de 2026 | Diário |
| ISCV · iShares Trust | · | 10.576 SH | 11 de Setembro de 2026 | Diário |
| SMLF · iShares Trust | · | 18.703 SH | 11 de Setembro de 2026 | Diário |
CRL Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
classificação · 23 analistas
COMPRA
Alvo mediano
$322.00
+11,0%
6 26,1%
Compra forte
11 47,8%
Compra
6 26,1%
Manter
0 0,0%
Venda
0 0,0%
Venda forte
Preço-alvo de 12 meses
15 analistas · 2026-10-02Alvo médio $305.00 +5,1%
Agora
Preço atual $290.19
Mín$145.00
Média$305.00
Máx$357.00
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | · |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | · |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TXG | $2.08B | -46.6 | 5.2% | -6.8% | -5.5% | 69.0% |
| TECH | $11.03B | 60.9 | -0.38% | 15.0% | 9.0% | 65.8% |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | · |
| AVTR | $7.82B | -14.7 | -3.4% | -8.1% | -8.9% | 32.6% |
| BIO | · | · | · | · | · | · |
Últimas notícias Notícias recentes mencionando esta empresa
Bio-Techne assume o 477º lugar, superando Charles River Laboratories International
Nasdaq · 3 meses atrás
Charles River Laboratories International Destaques da Chamada de Lucros do Q1
Yahoo Finance · 4 meses, 3 semanas atrás
Títulos do Tesouro dos EUA Tokenizados se Aproximam de US$ 14 Bilhões, com Circle e BlackRock Liderando o Crescimento
Yahoo Finance · 5 meses, 2 semanas atrás
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Fonte: SEC 10-Q arquivado Ago 5, 2026